Unit

UNIT 14.13 Pre-Clinical Models of Renal Carcinoma and Their Utility in Drug Development

  1. Brenda C. Salumbides1,
  2. Kristin M. Lehet2,
  3. Georges Ndikuyeze1,
  4. Roberto Pili1,2

Published Online: 1 DEC 2009

DOI: 10.1002/0471141755.ph1413s47

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Salumbides, B. C., Lehet, K. M., Ndikuyeze, G. and Pili, R. 2009. Pre-Clinical Models of Renal Carcinoma and Their Utility in Drug Development. Current Protocols in Pharmacology. 47:14.13:14.13.1–14.13.19.

Author Information

  1. 1

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

  2. 2

    Roswell Park Cancer Institute, Buffalo, New York

Publication History

  1. Published Online: 1 DEC 2009
  2. Published Print: DEC 2009

Abstract

Significant progress has been made in the treatment of patients with advanced renal cancer. In addition to immunotherapy, there are several potentially distinct therapeutic approaches for targeting molecular pathways. The murine models detailed in this unit are useful for testing rational combination strategies. Moreover, animal models contribute immensely to the understanding of the genetic, epigenetic, and biological aspects of human disease. Compared to humans, rodent models are relatively short-lived and allow for the facile study of clinically relevant pathologies. Animal models for the study of renal cell carcinoma (RCC) are particularly useful for the development of new drugs for kidney cancer. Included in this unit are several in vivo models that are currently used to evaluate therapeutic approaches to renal cancer therapy and to investigate the pathophysiology of this condition. Included are both murine (RENCA) and renal cell carcinomas in subcutaneous and orthotopic models using tumor cell lines and human tumor tissue. Curr. Protoc. Pharmacol. 47:14.13.1-14.13.19. © 2009 by John Wiley & Sons, Inc.

Keywords:

  • renal cell carcinoma;
  • metastastic tumor;
  • xenograft model;
  • orthotopic implantation;
  • subcutaneous implantation;
  • angiogenesis;
  • bioluminescent imaging;
  • immunotherapy;
  • combination therapy;
  • retinoids